For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Control | no steroid or non steroidal anti-inflammatory Placebo: Control | 0 | None | 0 | 11 | 0 | 11 | View |
| Ketorolac | one time dose of 30mg of IV Ketorolac at time of closure Intravenous Ketorolac: To assess the efficacy of the meds for dysphagia and dysphonia following ACDF | 0 | None | 0 | 10 | 0 | 10 | View |
| Dexamethasone | one time dose of 10mg of IV dexamethasone at the time of closure Intravenous Dexamethasone: To assess the efficacy of the meds for dysphagia and dysphonia following ACDF | 0 | None | 0 | 12 | 0 | 12 | View |